. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: Nat Rev Clin Oncol. 2016 Mar 22;13(9):566–579. doi: 10.1038/nrclinonc.2016.35

Table 1.

Clinicopathological characteristics of the NeoALTTO and ALTTO trials

Characteristic	NeoALTTO (n = 455)	ALTTO (n = 8,381)
Primary end point	Breast pCR	DFS
Approach to dual HER2 blockade	Lapatinib plus trastuzumab	Lapatinib plus trastuzumab, or trastuzumab then lapatinib
Menopausal status	NA	Postmenopausal or male: 56–57% (0–0.25% male) Premenopausal: 43–44%
Tumour size^*	≤ 2cm: 1.3–2.6% >2cm and ≤5: 44.3–61.8% >5 cm: 35.5–53% Missing or NA: 0–1.3%	≤ 2cm: 41% >2cm and ≤5: 44–45% >5 cm: 5–6% Missing or NA: 9–10%
Axillary-lymph-node status^*	N0–1: 83.8–84.6% ≥N2, Nx, or missing: 15.4–16.2%	N0: 40% N1–3: 29–30% ≥N4: 22% Missing or NA: 8–9%
ER status^*	ER negative: 48.1–49.7% ER positive: 50.3–51.9%	ER negative: 42–43% ER positive: 57–58%

Ranges represent the different values across treatment arms.

DFS, disease-free survival; ER, oestrogen receptor; N, regional lymph node stage; NA, not available; Nx, regional lymph nodes could not be assessed (for example, previously removed); pCR, pathological complete response.